Search
for

    Learn

    5 / 801 results

    Research

    5 / 72 results

    Community Join

    5 / 1000+ results

      community The story of RU58841/PSK3841

      in Research/Science 1 year ago
      RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

      community PP405 Update and My Take on Pelage

      in Research/Science  86 upvotes 5 months ago
      Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.